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MYELOID NEOPLASIA
ICSBP-mediated immune protection against BCR-ABL–induced leukemia
requires the CCL6 and CCL9 chemokines
Valentina Nardi,1 *Olaia Naveiras,1 *Mohammad Azam,1 and George Q. Daley1
1Division of Hematology/Oncology, Children’s Hospital Boston and Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, MA
Interferon (IFN) is effective at inducing
complete remissions in patients with
chronic myelogenous leukemia (CML),
and evidence supports an immune mecha-
nism. Here we show that the type I IFNs
(alpha and beta) regulate expression of
the IFN consensus sequence-binding pro-
tein (ICSBP) in BCR-ABL–transformed
cells and as shown previously for ICSBP,
induce a vaccine-like immunoprotective
effect in a murine model of BCR-ABL–
induced leukemia. We identify the chemo-
kines CCL6 and CCL9 as genes promi-
nently induced by the type I IFNs and
ICSBP, and demonstrate that these immu-
nomodulators are required for the immu-
noprotective effect of ICSBP expression.
Insights into the role of these chemo-
kines in the antileukemic response of
IFNs suggest new strategies for immuno-
therapy of CML. (Blood. 2009;113:3813-3820)
Introduction
Chronic myelogenous leukemia (CML) results from a chromosomal
translocation in a hematopoietic stem cell that generates the BCR-ABL
oncogene. CML initially manifests as a chronic myeloproliferative
disease with anemia, extreme granulocytosis, basophilia, splenomegaly,
and often thrombocytosis. If left untreated, the disease progresses to
acute leukemia (“blast crisis”) and a fatal outcome. Although CML
accounts for less than one-fifth of all cases of leukemia, it has frequently
served as a paradigm in oncology, both for understanding the molecu-
lar basis of cancer and for developing novel approaches to therapy.
Several types of therapeutic modalities now commonly used to treat
cancer such as bone marrow transplantation, interferons (IFNs), and
molecularly targeted protein kinase inhibitors were first introduced as
treatments for CML.
The BCR-ABL oncogene encodes the BCR-ABL fusion onco-
protein, a deregulated tyrosine kinase. BCR-ABL phosphorylates
tyrosines in various substrates and activates multiple intracellular
signaling pathways involving RAS, nuclear factor B (NFKB), and
phosphatidylinositol 3-kinase (PI3K).1-5 Despite the indisputable
success of small molecule inhibitors of BCR-ABL in prolonging
the survival of patients with CML, these agents are rarely curative
and treated patients can relapse with drug-resistant disease. Thus,
there is a recognized need for additional approaches to complement
BCR-ABL inhibitors in the treatment of CML.
Biologic therapies are one alternative strategy with proven success in
treating CML. IFN alpha, until recently considered first-line therapy for
CML, induces long-term survival and complete cytogenetic responses
that are maintained for many years, even off therapy, in a subset of
patients. Although some argue that IFN alpha can be curative,6-8 most
“disease-free” patients retain BCR-ABL–positive cells.9,10 Therefore,
rather than eradicating the disease, IFN alpha appears to induce a
long-term state of “tumor dormancy.”11 Alternatively, IFN alpha might
reduce the number of CML clones below a certain threshold so that they
have a low probability of regrowing. The immunomodulatory properties
of IFN alpha play a pivotal role in its activity as an anticancer agent for
CML,12 and there is a strong correlation between the presence of
cytotoxic T lymphocytes (CTLs) specific for certain tumor antigens,
such as proteinase 3, and clinical responses to IFN alpha.13,14 The
downstream molecules through which IFN alpha induces its antileuke-
mic effects and how these connect to pathways deregulated in CML
remain poorly understood.
In addition to the central role of BCR-ABL in CML pathogene-
sis, there is substantial evidence that the IFN consensus sequence-
binding protein (ICSBP; also known as IFN regulatory factor 8 [IRF8])
is a tumor suppressor in CML.15-20 Mice lacking ICSBP die from a
malignancy that is remarkably similar to CML.15 Patients with
CML have low levels of ICSBP in BCR-ABL–expressing cells, and
successful CML therapy is associated with a restoration of ICSBP
levels.21 Lastly, the expression of ICSBP in BCR-ABL–transformed
cells abolishes their capacity to cause leukemia in a syngeneic
mouse leukemia model by inducing a long-lasting, T cell–mediated
response against antigens preferentially expressed on BCR-ABL–
transformed cells.17
Much is known about the normal physiologic role of ICSBP in
controlling macrophage and dendritic cell differentiation.22-25 However,
how ICSBP is regulated in CML cells and the downstream pathways
through which it induces an antileukemic response remain unclear.
Here, we show that INF alpha up-regulates ICSBP expression in
BCR-ABL–transformed cells and can substitute for ICSBP overexpres-
sion in protecting mice from leukemia. We show that ICSBP can act in a
non–cell-autonomous fashion by up-regulating the expression of the
chemokines CCL6 and CCL9, which we demonstrate are key mediators
of the antileukemic effects of ICSBP.
Methods
Mice and analysis of murine leukemia
Female Balb/c- and Rag 2–deficient mice (6-9 weeks old; The Jackson
Laboratory, Bar Harbor, ME) were injected intravenously with
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105 to 106 parental BaF3 cells or BaF3 cells expressing different genes
(see “Cell lines, plasmids, and retroviral and lentiviral constructs”).
Mice were closely monitored and killed if moribund and peripheral
blood was harvested for both complete blood count (CBC) and flow
cytometric analysis before being killed. Peripheral blood smears were
prepared and stained with eosin solution azure A and methylene blue.
Spleen size and weight was determined in mice found dead. Some
spleens harvested from killed animals were used for RNA and DNA
isolation and to obtain single-cell suspensions of splenocytes for flow
cytometry analysis. Research with mice was approved by the institu-
tional review board of Children’s Hospital Boston.
Cell lines, plasmids, and retroviral and lentiviral constructs
BaF3 cells, a murine pro–B-cell line26 and the murine myeloid precursor
line 32Dcl3 (hereafter referred to as 32D) were maintained in complete
RPM 1640 supplemented with 10% conditioned medium from WEHI-3B
cells, as a source of IL-3. The human CML cell lines K562, Lama 84, and
AR 230 were maintained in complete RPMI medium. Peripheral blood
mononuclear cells from healthy volunteers were purchased from AllCells
(Emeryville, CA) and maintained in complete RPMI medium. Murine and
human cells were treated with IFN alpha 2A or IFN beta (R&D Systems,
Minneapolis, MN), as described in the figure legends.
BaF3 BCR-ABL cell lines were generated by infecting BaF3 cells with
different retroviral constructs expressing BCR-ABL. Full-length BCR-
ABL cDNA was inserted into the EcoRI site of the pEYK3.1 retroviral
vector,27 generating pEYKBA. Similarly, the BCR-ABL cDNA was in-
serted into the EcoRI site of pBabe-puro and of MSCV-IRES-GFP
retroviral vectors. Cells infected with these different constructs were
selected with IL-3 independence, 2.5 g/mL puromycin or sorting for green
fluorescence protein (GFP)–high cells, respectively. BaF3 BCR-ABL
mutants L248R and T315I were generated as previously described.27 32D
cells expressing BCR-ABL were generated by infecting cells with VSVG-
pseudotyped pBabe-puro BCR-ABL retrovirus. BaF3 cells expressing
ICSBP, IFN alpha, or IFN beta were generated by infecting BaF3 cells with
retroviral constructs expressing cDNAs for ICSBP, IFN alpha, or IFN beta.
The cDNAs were obtained in our laboratory by reverse transcription–
polymerase chain reaction (RT-PCR), verified by sequencing, and sub-
cloned into the EcoRI sites of the pBabe-puro or MSCV-IRES-GFP
retroviral vectors. Cells were then selected with 2.5 g/mL puromycin or
by sorting for GFP-high cells, respectively. BaF3 CCL6 and BaF3 CCL9
cell lines were generated by infecting BaF3 cells with retroviral superna-
tants prepared from pBabe-puro CCL6 or pBabe-puro CCL9 cDNAs for
CCL6 and CCL9 were generated from Balb/c cDNA and subcloned into the
EcoRI sites of pBabe-puro. Retroviral supernatants were produced as
previously shown.28
We used both the Lentilox 3.7 and TRC pLKO.1 lentiviral short hairpin RNA
(shRNA) vectors for RNA interference against CCL6, CCL9, ICSBP, luciferase,
and LacZ genes. shRNAs for the Lentilox vector were designed as described
(http://jura.wi.mit.edu/siRNAext/), while those in the TRC pLKO.1 vector were
purchased (Sigma-Aldrich, St Louis, MO). The extents of gene knockdown for
the chemokines were calculated by performing a semiquantitative PCR. PCRs
were performed on serially diluted samples of RNA isolated from cells infected
with control shRNAs or the shRNAs targeting the chemokines.After running the
PCRs on agarose gels the intensity of the PCR bands stained with ethidium
bromide was compared between the control and experimental samples to
determine the level of knockdown. Serial dilutions were chosen so that the PCRs
gave band intensities that correlated linearly with the amount of sample in each
reaction. Figure 4 shows a representative image for PCRs performed on 1:8
dilutions of the samples.
Flow cytometric analysis, cell sorting, and cell blood counts
Mouse peripheral blood was collected by retro-orbital bleeding of the animals
through heparin-coated capillary tubes. Peripheral blood counts were performed
using the Hemavet 950 (Drew Scientific, Dallas, TX) instrument. Splenocytes
were obtained by reducing mouse spleen to single-cell suspensions, using 40M
filters. Growing BaF3 cells (0.5 106 log phase), native or expressing BCR-
ABL, ICSBP or ICSBP, and BCR-ABL were also used for flow analysis. All cell
types were preincubated with mouse anti-CD16/CD32 antibody to block
nonspecific binding via Fc receptors (BD Pharmingen, San Diego, CA) for
30 minutes. Subsequently, the samples were washed and incubated with 0.5% of
the following monoclonal antibodies: anti–CD3-allophycocyanin (APC) conju-
gated and anti–CD8-phycoerythrin (PE) conjugated, anti–CD4-PE conjugated,
anti–CD56-PE or anti–IgM-APC conjugated and anti–CD19-PE conjugated or,
finally, anti-D11b (Mac1)–APC conjugated and anti–CD86 (B7.2)–PE conju-
gated (all antibodies were from BD Pharmingen). Isotype controls were run
each time. The samples were analyzed using a FACSCalibur cytometer and
FlowJo software.
BaF3 cells infected with MSCV-ICSBP-Ires-GFPor MSCV-BCR-ABL-Ires-
GFP retroviruses or BaF3 cells infected with lentilox-3.7 GFP for the expression
of hairpins against CCL6, CCL9, and Lac Z were filtered through a 70m filter
and sorted for GFP high on a MoFlo instrument (Dako, Carpinteria, CA) at the
Massachusetts Institute of Technology (MIT) Cancer Center and at the Dana-
Farber Cancer Institute Sorting Facilities.
Qualitative and quantitative RT-PCR
mRNA was isolated from cell lines or spleens preserved in RNA later
(QIAGEN, Valencia, CA), using the RN-easy kit (QIAGEN) and subjected
to on-column DNAse digestion (QIAGEN). cDNA was obtained by reverse
transcription of 100 ng to 2 g RNA, after DNAse digestion (QIAGEN),
using the Superscript II enzyme (Invitrogen, Carlsbad, CA). Taq polymer-
ase (CLP) was used for the qualitative RT-PCR (see Table S1 for primer
sequences, available on the Blood website; see the Supplemental Materials
link at the top of the online article). For real-time PCR, the Brilliant Q-PCR
SYBR green master mix (Stratagene, La Jolla, CA) and the Stratagene and
Bio-Rad instruments were used and primers were purchased from Realtime
primers (Elkins Park, PA) and Superarrays (Frederick, MD). RT controls
were run in parallel with the correspondent samples. Data were analyzed
with the cycle threshold (Ct) comparative method using actin as a
housekeeping gene. Other investigators studying ICSBP function in the
context of CML have also used actin as a control gene.12,18
Microarray analysis
Total RNA (15 g) was isolated from parental BaF3 cells, or BaF3 cells
expressing either ICSBP or BCR-ABL, or ICSBP and BCR-ABL. Af-
fymetrix mouse whole genome arrays 430_2 were used for the analysis.
Probe labeling, chip hybridization, and chip scanning were performed at the
Biopolymer Facility at Harvard Medical School. Each chip was normalized
to the median expression on the chip. A threshold value of 50 was set for all
genes and the list of genes filtered to include only those that had at least one
present flag (“P” flag) in 1 of the 4 conditions. For each gene, the ratio of its
expression in a particular condition and its expression in parental BaF3 cells
was determined. Only genes that had at least a 3-fold up or down change in
expression were considered, leaving a set of 1431 genes for further analysis.
K-means clustering with Gene cluster 3.0 was used to group these 1431
genes into 15 clusters and JavaTree was used to visualize the results. The
microarray data can be found in the public database Gene Expression
Omnibus (GEO) under accession number GSE14416.
Statistics
We expressed data as arithmetic means with standard deviation (SD) and
performed statistical analysis as indicated in the figure legends. All data are
obtained from independent measurements.
Results
Type I IFNs induce ICSBP expression in mouse and human
BCR-ABL–transformed cells
The ICSBP transcription factor is exclusively expressed in immune
system cells and was first identified as a gene regulated by IFN
gamma, a type II IFN (IFN).29 Treatment of patients with CML
with IFN alpha results in increased levels of ICSBP expression in
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peripheral blood cells,21 but it remains unclear whether type I IFNs
directly up-regulate ICSBP expression. We explored the relation-
ship between IFN alpha and ICSBP expression in murine pro–B-
lymphoid BaF3 cells, which have been used extensively as a
syngeneic mouse model of BCR-ABL–induced leukemia,30,31 and
in human primary cells and cell lines from patients with CML. In
BaF3 cells, addition of murine IFN alpha or beta to the cell media
greatly increased ICSBP levels in the parental and BCR-ABL–
transformed cells (Figure 1A,B). A similar up-regulation was seen
in the murine myeloid cell line 32D (Figure 1C), in peripheral
blood mononuclear cells from a healthy human volunteer, and in
both the K562 and AR230 human CML cell lines (Figure 1D).
These results establish that type I IFNs can activate ICSBP
expression in both normal and CML cells from mouse and human.
Type I IFNs are as effective as ICSBP in conferring
immune-mediated antileukemia protection
We have shown previously that ICSBP overexpression in BCR-ABL–
transformed BaF3 cells elicits a vaccine-like antileukemic immune
response.17 As type I IFNs induce ICSBP expression in BCR-ABL–
transformed cells, we reasoned that IFN alpha or beta expression might
also protect mice from leukemia. To test this, we expressed ICSBP, IFN
alpha, or IFN beta in BaF3 cells transformed by BCR-ABL. In tissue
culture, the expression of these proteins did not affect the proliferation
rate of the BaF3 BCR-ABL cells (data not shown). We then injected
these cells into syngeneic Balb/c mice. As expected, mice injected with
cells expressing only BCR-ABL developed leukemia and died 2 to
4 weeks after injection, while those receiving cells coexpressing
ICSBP and BCR-ABL remained disease-free for at least 28 weeks
after injection (Figure 1E and data not shown). When expressed in
BCR-ABL–transformed cells, both IFN alpha and beta were as
effective as ICSBP in preventing leukemia in the mice (Figure 1E
and data not shown). Expression of reverse orientation cDNAs for
IFN alpha did not provide antileukemic protection (Figure S1B),
and, as shown for ICSBP,17 the protection conferred by the IFNs
required intact immunity, as it was not observed in immunodefi-
cient Rag 2 knockout mice (Figure S1A). Patients with CML
treated with imatinib and newer generation BCR-ABL inhibitors
can develop resistance to these drugs by acquiring point
mutations in the kinase domain of BCR-ABL. Expression of
ICSBP and the type I IFNs rescued mice from leukemias caused
by imatinib-resistant BCR-ABL mutants commonly found in
patients with CML, including the infamous T315I BCR-ABL
mutant (Figure S2A,B).
Figure 1. Type I IFNs induce ICSBP expression and rescue mice from a BCR-ABL–induced leukemia. RT-PCR and Q-RT-PCR showing the expression of ICSBP before and at
different time points after IFN alpha or IFN beta treatment (104 U/mL unless otherwise specified) in (A) parental BaF3 cells (n 3 standard deviation); (B) BaF3 cells transformed with
BCR-ABL; (C) parental and BCR-ABL transformed 32D cells; and (D) healthy human peripheral blood mononuclear cells (hPBMCs) and human CML cell lines AR230 and K562. Similar
results were obtained from hPBMCs from 3 different healthy donors. (E) Cell-autonomous protection against leukemia conferred by ICSBP and type I IFNs. Survival curves of 6- to
9-week-old Balb/c mice injected with 106 BaF3 cells expressing the indicated cDNAs.At least 2 experiments per condition were performed, each containing 5 to 10 mice for each cell type.
(F) Non–cell-autonomous protection against leukemia conferred by ICSBP and type I IFNs. Survival curves for 6- to 9-week-old Balb/c mice injected with 0.5 106 BaF3 cells separately
expressing indicated cDNAs.At least 2 experiments per condition were performed, each containing 5 to 10 mice for each cell type.
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IFNs and ICSBP act in a non–cell-autonomous manner
Given that IFNs are secreted proteins, we asked whether they could
exert a vaccine-like effect if delivered in nonleukemic parental
BaF3 cells. Indeed, the IFNs protected nearly 100% of the mice
even when expressed in different cells than BCR-ABL (Figure 1F).
Unexpectedly, even ICSBP, an intracellular regulator of transcrip-
tion, gave a substantial but incomplete degree of antileukemic
protection to mice when it was expressed in separate cells (Figure
1F). A potential explanation for these results is that the expression
of ICSBP in nonleukemogenic cells triggers the production of a
secreted or cell-surface molecule that mediates protection against
the leukemia induced by transformed BCR-ABL cells.
Identification of candidate genes for mediating the
antileukemic effects of ICSBP
To explore how ICSBP induces protection against the BCR-ABL–
induced leukemia, we performed transcriptional profiling to
identify candidate genes that mediate its non–cell autonomous
effects. We reasoned that such genes should be induced by
ICSBP in parental and BCR-ABL–transformed BaF3 cells. We
used microarrays covering all mouse genes to profile parental
BaF3 cells as well as BaF3 cells expressing BCR-ABL, ICSBP,
or both BCR-ABL and ICSBP. Using k-means clustering, we
organized genes into 15 different clusters that reflected their
varying expression patterns across the 4 cell lines (“Microarray
analysis” in “Methods” and Figure S3). Four gene clusters were
particularly interesting. Clusters 1 and 2 contain genes whose
expression was increased or decreased by ICSBP, respectively,
but not affected by BCR-ABL. Clusters 3 and 4 contain genes
whose expression was increased or decreased by BCR-ABL,
respectively, and normalized by coexpression with ICSBP.
Consistent with known results, cluster 3 contains cyclin D1 and
NFKBP, genes whose expression is induced by BCR-ABL and
normalized by ICSBP and which may participate in BCR-ABL–
driven cell transformation.32,33
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Figure 2. ICSBP and the type I IFNs regulate expression of the CCL6 and CCL9 chemokines. (A) Cluster analysis of the genes that changed at least 3-fold in expression
among pairwise comparisons of the 4 indicated cell types: parental BaF3 cells, or BaF3 cells expressing BCR-ABL (BaF3 BA), ICSBP, or ICSBP and Bcr-Abl (ICSBP BA).
Expression was normalized to that in parental BaF3 cells. Four clusters containing genes that reflect ICSBP-regulated expression are illustrated. The colors signify the
magnitude and direction of the changes in gene expression. To the right of the clusters are the gene functional categories enriched in each and examples of genes present in
each category. The numbers in parentheses indicate the number of times each gene appeared in a cluster. (B) RT-PCR validation of gene expression for several of the genes
detected by gene expression profiling within the indicated cell types. (C) Confirmation by RT-PCR that genes regulated by ICSBP are also regulated by treatment with 104 U/mL
IFN alpha or beta for 6 hours in the indicated cell types. In some cases the IFNs restore expression of a gene that is otherwise down-regulated by BCR-ABL. (D) Requirement of
ICSBP for IFN alpha to induce CCL6 and CCL9 expression. RT-PCR was used to detect expression of indicated genes in BaF3 parental cells expressing a control shRNA or an
shRNA that decreases the expression of ICSBP. Cells were analyzed before and after treatment with IFN alpha (104 U/mL for 6 hours). (E) RT-PCR showing CCL23 and CCL15
expression in the human AR230 CML cell line upon treatment with 104 U/mL IFN alpha. (F) RT-PCR showing CCL23 and CCL15 expression in normal human PBMCs upon
treatment with 104 U/mL IFN alpha for 1 hour.
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Cluster 1 is heavily enriched for genes involved in macrophage
function, such as Fc receptors and cathepsins, suggesting that ICSBP
expression may promote the differentiation of the cells into macro-
phages or antigen-presenting cells. However, extensive FACS analysis
of macrophage cell-surface markers failed to support this hypothesis for
BaF3 cells (“Flow cytometric analysis, cell sorting, and cell blood
counts” in “Methods” and data not shown). As we were particularly
interested in genes that could mediate the non–cell-autonomous effects
of ICSBP, we focused on genes in cluster 1 that encode secreted proteins
that engage the immune system. The genes most highly up-regulated by
ICSBP in cluster 1 were the related CCL6 and CCL9 chemokines,
which were increased 10- to 20-fold (Figure 2A,B). The functions of
these chemokines are not well understood, but they are thought to act as
chemoattractants for CD4 and CD8 T lymphocytes as well as
monocytes.34 Using RT-PCR, we verified the transcriptional profiling
results for CCL6 and CCL9 as well as for many other highly regulated
genes (Figure 2B). Consistent with type I IFNs inducing ICSBP, murine
IFN alpha and beta also induce the expression of CCL6 and CCL9 in
parental and BCR-ABL–transformed BaF3 cells (Figure 2C). The
effects of IFN alpha are mediated by ICSBP, because in cells where
ICSBP expression is reduced using RNA interference (RNAi), IFN
alpha no longer induces CCL6 and CCL9 expression (Figure 2D).
Furthermore, in human AR230 CML cells and normal PBMCs, human
IFN alpha induces the expression of CCL15 and CCL23, the human
orthologues of CCL6 and CCL9, respectively (Figure 2E,F). Our
transcriptional profiling data demonstrate that enforced expression of
ICSBP can counteract some of the deregulation in gene expression
caused by BCR-ABL. More importantly, we identify the CCL6 and
CCL9 chemokines as genes strongly induced by ICSBP and IFN alpha
in mouse and human CML cells.
CCL6 and CCL9 are necessary but not sufficient to induce the
antileukemic immune protection mediated by ICSBP
We explored the possibility that the CCL6 and CCL9 chemokines
might participate in the antileukemic immune protection caused by
the expression of ICSBP in BCR-ABL–transformed cells. We
tested the role of CCL6 and CCL9 by overexpressing each
chemokine in parental BaF3 cells and coinjecting them with
BCR-ABL–expressing leukemogenic cells into syngeneic mice
(Figure 3A). While the expression of the 2 chemokines alone (data
not shown) or in combination could not fully rescue the mice from
developing leukemia, it consistently and significantly delayed
disease progression by several weeks (Figure 3B,C). Protection
from leukemia progression was mediated by the immune system, as
it did not occur when the same cells were injected in immunocom-
promised mice (Figure 3C). These data suggest that CCL6 and
CCL9 contribute to, but are not themselves sufficient to confer, an
antileukemic immune response.
To determine whether CCL6 and CCL9 are necessary for
ICSBP to mediate its antileukemic action, we used RNAi to
decrease CCL6 or CCL9 expression in BaF3 cells that coexpress
BCR-ABL and ICSBP (and thus do not cause leukemia when
injected into mice). To implement RNAi, we targeted each
chemokine with 2 independent shRNA-expressing lentiviruses.35,36
Compared with cells expressing either of 2 control shRNAs
(targeting luciferase or LacZ), cells expressing the chemokine-
specific shRNAs caused a greater than 80% reduction (“Cell lines,
plasmids, and retroviral and lentiviral constructs” in “Methods”) in
the expression of their respective targets (Figure 4A). As before, all
control mice injected with BaF3 cells expressing BCR-ABL died
within 5 weeks, while all those injected with BaF3 cells coexpress-
ing BCR-ABL and ICSBP survived for the course of the experi-
ment. The expression of the control shRNAs did not prevent the
antileukemic effects of ICSBP. In contrast, mice injected with cells
coexpressing BaF3, ICSBP, and shRNAs that reduce CCL6 or
CCL9 expression died within 4 to 7 weeks after injection (Figure
4B). The leukemia observed in these mice was indistinguishable
from that caused by the injection of BaF3 cells expressing only
BCR-ABL. The mice had massive splenomegaly, anemia, and
leukocytosis with relative lymphopenia (Figure S4). Moreover, by
exploiting the fact that the BCR-ABL–expressing BaF3 cells also
coexpress GFP, we determined that the diseased mice have high
BCR-ABL–positive blast counts in the peripheral blood and spleen
(Figure 4C-E). We verified that a knockdown in expression of
CCL6 or CCL9 does not also lead to a change in the expression of
the other chemokine (data not shown). In experiments using
shRNAs that did not give effective chemokine knockdown, the
vaccine-like effect of ICSBP expression persisted (data not shown).
Taken together, our data indicate that both the CCL6 and CCL9
chemokines are necessary, although alone not sufficient, for ICSBP
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Figure 3. CCL6 and CCL9 are not sufficient to induce full protection against a BCR-ABL–induced leukemia. (A) RT-PCR showing BCR-ABL, CCL9, and CCL6
expression in the BaF3 cells injected into mice. (B) CCL6 and CCL9 cannot substitute for ICSBP in conferring immune protection from leukemia. Survival curves for 6- to
9-week-old Balb/c mice injected with 0.3  106 BaF3 cells expressing BCR-ABL alone (), or together with 0.15  106 BaF3 cells expressing CCL6 and 0.15  106 BaF3 cells
expressing CCL9 (‚). Experiment was repeated 3 times, with n  15 for each condition. Unpaired t test shows significance at P  .003 for differences in survival curves.
(C) CCL6 and CCL9 promote survival only in immunocompetent mice. Survival curves obtained for 9- to 12-week-old Rag 2/ mice injected with 3  105 BaF3 cells
expressing BCR-ABL alone () or together with 3  105 BaF3 cells expressing CCL6 and 3  105 BaF3 cells expressing CCL9 (‚). N  10 for each condition.
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to confer immune protection against a BCR-ABL–induced leuke-
mia in mice.
Discussion
Several lines of evidence suggest that immunotherapy can play a
major role in the treatment of CML. Clinical experience shows that
a graft-versus-leukemia (GVL) effect is highly relevant to the
long-term remissions achieved after bone marrow transplanta-
tion37,38 and that adoptive immunotherapy through donor lympho-
cyte infusions (DLIs) can cure CML in some relapsed patients.39-41
Similar results have been observed in mouse models of the disease,
where donor T cells transferred during bone marrow transplanta-
tion can effectively control the leukemic cells.42 A fraction of
patients with CML treated with IFN alpha develop cytotoxic
T lymphocytes that target leukemic cells,12,14 suggesting that IFNs
can mediate an antileukemic immune response.
Expression of ICSBP in BCR-ABL–transformed cells prevents
their capacity to cause leukemia in a syngeneic mouse model of
leukemia by inducing a T lymphocyte–mediated immune response
against the leukemic cells.17 In this study, we examined the
relationship between ICSBP and type I IFNs, and found that IFN
alpha induces ICSBP expression in nontransformed and in BCR-
ABL–expressing cells, and that IFN alpha and ICSBP are equally
effective at inducing the antileukemic immune response in our
model. Because we found that ICSBP can act in a non–cell-
autonomous fashion, we searched for secreted factors that partici-
pate in its antileukemic activity and identified CCL6 and CCL9 as
related chemokines produced by cells after ectopic expression of
ICSBP or treatment with type I IFNs. CCL6 and CCL9 are
proinflammatory chemokines that serve as chemoattractants for
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Figure 4. CCL6 and CCL9 are necessary for ICSBP-dependent protection against BCR-ABL–induced leukemia. (A) RT-PCR showing down-regulation by indicated
lentiviral shRNAs of CCL6 and CCL9 expression in BaF3 cells that overexpress ICSBP and BCR-ABL. Two effective shRNAs were used for each chemokine; the control
shRNA targeted luciferase. (B) Reduced expression of CCL6 or CCL9 prevents the antileukemic survival response normally mediated by ICSBP. Survival curves obtained after
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3818 NARDI et al BLOOD, 16 APRIL 2009  VOLUME 113, NUMBER 16
 For personal use only.2014. 
 at ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE on March 24,bloodjournal.hematologylibrary.orgFrom 
CD11b, IFN-producing dendritic cells, NK cells, and CD4
T cells.43,44 Cells transformed by BCR-ABL down-regulate CCL6
and CCL9 expression. Both chemokines are necessary for the
antileukemic immune response mediated by ICSBP, and while their
expression cannot substitute for ICSBP, it does significantly delay
leukemia progression and death in the murine model of CML,
suggesting that CCL6 and CCL9 are necessary, but not sufficient to
mediate the immunoprotective effects of ICSBP in our model.
Although it is possible that ICSBP might directly transactivate the
CCL6 and CCL9 genes, the mechanism of chemokine up-
regulation is not known.
Previously, it was shown that CCL9 expression is reduced in murine
32D cells transformed by BCR-ABL and restored to normal levels by
Gleevec treatment. Furthermore, overexpression of CCL9 in the trans-
formed cells reduced their leukemic capacity, likely by modulating a
T-cell response against the leukemic cells.45 Down-regulation of CCL6
and CCL9 chemokines by BCR-ABL could be one mechanism adopted
by the leukemic cells to evade the immune system. Our work indicates
that CCL6 and CCL9 are induced in normal cells and reactivated in
leukemic cells by IFN alpha treatment. IFN is known to normalize some
activities of the immune system that are otherwise impaired in patients
with CML. For example, IFN alpha restores NK and T-cell function in
patients with CML46,47 and induces CML mononuclear cells to differen-
tiate toward antigen-presenting dendritic cells.46 Our findings, together
with the prior clinical observation that ICSBP levels are restored in
patients with CML who respond to IFN alpha, suggest a key role for
ICSBP and CCL15 and CCL23, the human orthologues of CCL6 and
CCL9, respectively, in mediating the therapeutic effects of IFN alpha in
CML. In preliminary studies, we have observed higher expression of
CCL23 in patients with CML who respond to treatment with IFN alpha,
relative to nonresponders (V.N., F. Castagnetti, M. Amabile, G. Rosti,
G. Martinelli, unpublished data, March 2008), and have observed
increased expression of the CCL15 and 23 chemokines after exposure
to IFN alpha of diverse malignant tumor cells, including multiple
myeloma, melanoma, renal cell carcinoma, and mycosis fungoides.
Coadministration of CCL15 and CCL23 might be a valuable adjunctive
therapy to the peptide vaccines that are currently in clinical development
as CML therapies,48 and may have wider therapeutic applications in
diverse tumor types.
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